

Sheffield Traffic Light Drugs List October 2024

Note: the BNF numbering system is based on the BNF legacy

Refer to the [user guide](#) for classification rationale

Remember : Control + F (see user guide for how to) to search this list

BNF Section	Drug	Rational : see introduction	Notes	Relevant links
OTC Preparations	Anti-fungal nail paints	4	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
OTC Preparations	Aspirin 300mg for acute pain in adults	4	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
10.2.2	Cannabis- based medicinal products	3	Black for all indications with the exception of those recommended in NICE NG144. See related entries in red section for: Cannabis extract - Delta-9-tetrahydrocannabinol & Cannabidiol (Sativex®) for spasticity in MS; Cannabidiol (Epidyolex®) for seizures associated with Dravet Syndrome & Lennox- Gastaut syndrome; and Nabilone for intractable nausea & vomiting.	NICE NG144
	Cod Liver Oil	4		
4.7.1	Co-codamol 8/500mg for acute pain in adults	4	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
	Co-enzyme Q10	3	For all indications except Friedreich's ataxia; See Co-enzyme Q10 in red section.	
OTC Preparations	Cough and cold remedies	4	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
	Electronic Cigarettes	4	Self-care should be encouraged and patients can be referred to the stop smoking service.	
OTC Preparations	Hayfever preparations (OTC antihistamines)	4	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
OTC Preparations	Ibuprofen 200mg - 400mg for acute pain in adults	4	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
15.2	Lidocaine plasters	4	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate. See also red and amber sections.	NICE CG173
4.5	Liraglutide (Saxenda®)	4	For use outside the NICE TA 664. See also Red and Amber sections.	
10.1.1	Mefenamic acid	4	Not approved for initiation in new patients diagnosed with dysmenorrhoea or menorrhagia.	
4.1.1	Melatonin	4	For unlicensed melatonin preparations, Colonis melatonin 3mg film coated tablets and Colonis melatonin 1mg/ml oral solution for jet lag in adults. Also see Amber and Green sections of TLDL and the Melatonin in treatment of Sleep Disorders in Children SCP .	

4.4	Modafinil	3	For new patients prescribed modafinil for unlicensed indications other than those approved by Medicines Safety Committee, STHFT (see red section). See amber section for licensed use in narcolepsy.	
10.3.2	NSAIDs (topical) diclofenac sodium, felbinac, ibuprofen, ketoprofen and piroxicam	4	For self-care. See also entry in Green section.	
4.7.2	Oxycodone and naloxone combination product (Targinact®)	4	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
OTC Preparations	Paracetamol for acute pain in adults	4	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
OTC Preparations	Probiotics	4	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
8.1.5	Ruxolitinib	2		NICE TA289
4.1.1	Sodium Oxybate	3	In adults, not previously treated with sodium oxybate for narcolepsy with cataplexy. See red section for children and for adults who have transitioned from children's to adult services and have already been prescribed this drug for narcolepsy.	
7.4.5	Tadalafil Once Daily 2.5mg/5mg (for Erectile Dysfunction)	4	See Sheffield STOP list for full details. See also entries in Red and Green sections.	
4.7.2	Tapentadol	3		
14.4	Varicella – Zoster vaccine (Zostavax®)	3	For routine vaccination against herpes zoster (shingles) other than in accordance with the national programme for vaccinating those aged 70 to 79 years.	
9.6.2	Vitamin B Compound/Compound Strong/Complex	4	See Sheffield STOP list for full details. Thiamine should be used for patients at high risk of developing Wernicke's encephalopathy.	
14.4	Yellow fever (Travel vaccines administered exclusively for the purpose of travel.)	4	See Sheffield STOP list for full details.	See local guidance for details of
7.4.5	Alprostadil	1, 2	If SLS criteria not met: a GP may provide a private prescription (detailed in HSC 1999/148) See also entry in amber section.	
2.8.2	Apixaban - For prevention of venous thromboembolism after total hip and knee replacement in adults. Note: full course to be provided by secondary care.	1, 5	See Amber and Green sections for other indications.	NICE TA245
4.2.3	Asenapine	1	SHSC have also stated that they would not be routinely initiating prescriptions.	
	Avacopan	1, 5	NHSE commissioned.	NICE TA825
For treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	Avatrombopag	1, 5		NICE TA626
10.1.3	Azathioprine	1, 5	When no agreed SCP available.	
	Berotrastat	1, 5	NHSE commissioned.	NICE TA738
8.2.4	Beta Interferon	1, 5		
8.1	Bexarotene	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
5.3.3.2	Boceprevir for the treatment of genotype 1 chronic hepatitis C	1, 5	http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c-cirrhosis-policy-statmnt-0615.pdf .	NICE TA253
1.5.2	Budesonide Orodispersible	1		
4.10.3	Buprenorphine	1, 5	As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-sheffield-treatment-and-recovery-team	

4.10.3	Buprenorphine prolonged-release injection (Buvidal®)	1, 5		
4.10.2	Bupropion Hydrochloride	5	Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/	
8.1	Busulfan	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
4.8	Cannabidiol (Epidyolex®)	1, 5	NICE TA614 with clobazam for seizures associated with Dravet Syndrome in people aged 2 years and older. See also related red entry for cannabidiol for Lennox Gastaut syndrome and black section for Cannabis-based medicinal products.	NICE TA614
4.8	Cannabidiol (Epidyolex®)	1, 5	NICE TA615 with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older. See also related red entry for cannabidiol in Dravet syndrome and black section for Cannabis-based medicinal products.	NICE TA615
10.2.2	Cannabis extract - Delta-9-tetrahydrocannabinol & Cannabidiol (Sativex®)	1, 5	For spasticity in MS; as in line with NICE NG144. See also related entry under Cannabis-based medicinal products in black section.	NG144
8.1	Capecitabine	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
10.1.3	Certolizumab Pegol	1, 5		
8.1	Chlorambucil	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
8.2.2	Ciclosporin	1	Unless disease specific shared care arrangement in place. Regular monitoring required. See: Common blood monitoring	
9.5.1.2	Cinacalcet	1, 5	To be prescribed by renal services, specialised commissioning. See Amber for primary hyperparathyroidism.	
4.2.1	Clozapine	1	Patients must be registered with the appropriate clozapine monitoring service. Prescribing physicians must also register themselves and a nominated pharmacist with the monitoring service.	
	Co-enzyme Q10	1, 4	For Friedreich's ataxia only; see Co-enzyme Q10 in black section.	
5.1.7	Colistimethate sodium (colistin sulfomethate sodium)	5	Specialised commissioning. To be prescribed by cystic fibrosis services. See also Amber section for non-cystic fibrosis bronchiectasis indication.	
8.1	Cyclophosphamide	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
2.8.2	Dabigatran etexilate - for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Note: full course to be provided by secondary care.	1, 5	See Amber and Green sections for other indications.	NICE TA157
2.8.1	Dalteparin	1	Unless guidance available.	
9.1.3	Darbepoetin alfa	1, 5	Renal Anaemia, specialised commissioning.	
5.3.1	Didanosine	1, 5	NHSE commissioned.	
8.2.4	Dimethyl fumarate (Skilarence®)	1, 5	For moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. NICE TA 475	
8.2.4	Dimethyl fumarate (Tecfidera®)	1, 5	NICE TA320	
5.3.1	Dolutegravir (including combinations)	1, 5	NHSE commissioned.	
3.7	Dornase Alfa	5	Specialised commissioning. To be prescribed by cystic fibrosis services.	
5.3.1	Efavirenz (including combinations)	1, 5	NHSE commissioned.	
5.3.3	Elbasvir with grazoprevir (Zepatier)	1, 5	NHSE commissioned.	NICE TA413
5.3.1	Elvitegravir (including combinations)	1, 5	NHSE commissioned.	
5.3.1	Emticitabine (including combinations)	1, 5	NHSE commissioned.	

5.3.1	Enfuvirtide	1, 5	NHSE commissioned.	
2.8.1	Enoxaparin	1	Unless guidance available.	
5.3.3	Entecavir	1, 5	NHSE commissioned. NICE CG165	NICE TA153
9.1.3	Epoetin alfa, beta & zeta	1, 5	Renal Anaemia, specialised commissioning.	
8.1	Estramustine phosphate	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
8.1	Etoposide	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
5.3.1	Etravirine	1, 5	NHSE commissioned.	
2.12	Evolocumab	1		NICE TA394
	Fenfluramine	1, 5	NHSE commissioned.	NICE TA808
10.1.3	Filgotinib	1, 5		NICE TA676
10.1.3	Filgotinib	1, 5		NICE TA792
8.2.4	Fingolimod	1		NICE TA254
5.3.1	Fosamprenavir	1, 5	NHSE commissioned.	
	Fostamatinib	1, 5		NICE TA759
4.7.4	Galcanezumab	1, 5		NICE TA659
	gammaCore	1		MTG 46
8.2.4	Glatiramer	1, 5	NHSE commissioned.	
5.3.3	Glecaprevir with pibrentasvir (Maviret®)	1, 5	NHSE commissioned.	NICE TA499
8.1.5	Hydroxycarbamide	1, 5	Red for all indications. In certain circumstances, in the patient's best interests, the blood monitoring may be undertaken by the GP at the request of the haematology specialist. The specialist will provide details of the tests required following each out-patient appointment.	
8.1	Idarubicin	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
2.5.1	Iloprost	1, 5	Patients treated for Pulmonary Arterial Hypertension.	
13.7	Imiquimod	1		
10.1.3	Infliximab	1, 5		
13.6.2	Isotretinoin	1		
Prescribing in Palliative Care	Ketamine	1	To be prescribed by Palliative Care Team.	
5.3.1	Lamivudine (including combinations)	1, 5	NHSE commissioned.	
9.5.2.2	Lanthanum	1, 5	To be prescribed by renal services, specialised commissioning.	
5.3.3	Ledipasvir with sofosbuvir (Harvoni®)	1, 5	NHSE commissioned.	NICE TA363
8.2.4	Lenalidomide	1		
15.2	Lidocaine plasters	1	Approved by Sheffield Teaching Hospitals for post operative neuropathic pain of chest drain site (thoracic surgery). This is mainly inpatient use but possibly on discharge for short period of time. Not for continued prescribing. Also, see Black and Amber sections.	NICE CG173
5.1.7	Linezolid	1, 5	Refer relevant patients to the STHFT oral linezolid OPAT service	
4.5	Liraglutide (Saxenda®)	1	The pathway for managing overweight and obesity, in line with NICE TA664 via a specialist tier 3 weight management service, is still being explored and so liraglutide (Saxenda®) is currently not able to be prescribed by primary care prescribers nor is it available through Live Lighter. If you have any patients who meet the criteria for use or have any queries, please e mail: APG mailbox . See also Black and Amber sections.	NICE TA664

8.1	Lomustine	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
5.3.1	Lopinavir with Ritonavir	1, 5	NHSE commissioned.	
9.1.4	Lusutrombopag	1, 5		NICE TA617
2.5.1	Macitentan	1, 5	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned.	
5.3.1	Maraviroc	1, 5	NHSE commissioned.	
4.10.3	Methadone	1, 5	As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-sheffield-treatment-and-recovery-team	
9.1.3.	Methoxy polyethylene glycol - epoetin beta	1, 5	Renal Anaemia, specialised commissioning.	
Prescribing in Ventricular arrhythmias	Mexiletine	1, 4	Ventricular arrhythmias - unlicensed indication not in BNF	
2.3.2	Mexiletine (Namuscla®)	1, 5	NHSE commissioned	NICE TA748
8.1	Mitotane	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
4.4	Modafinil	1, 5	For new patients prescribed modafinil for unlicensed indications, approved by Medicines Safety Committee, STHFT, as listed in the Modafinil SCP . See black section for other unlicensed indications and amber section for licensed use in narcolepsy.	
8.2.1	Mycophenolate	1, 3	Specialised commissioning; to be prescribed by specialist services for transplant recipients. See also amber section for Adult rheumatology patients with connective tissue disease.	
4.6	Nabilone	1, 5	For intractable nausea and vomiting.	NICE NG144
4.10.1	Nalmefene	1, 5	Sheffield Alcohol Service: https://shsc.nhs.uk/service/sheffield-alcohol-services/	NICE TA325
5.3.1	Nevirapine	1, 5	NHSE commissioned.	
1.10.2	Nicotine	5	Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/	
14.5.1	Normal Immunoglobulin	1, 2	Home therapy booklet for GPs	
Prescribing in primary biliary cholangitis	Obeticholic acid	1, 5		NICE TA443
4.2.2	Olanzapine (depot injection)	1	SHSC have stated that they would not be routinely initiating prescriptions.	
4.6	Ondansetron	1	Not normally indicated for primary care use. For unlicensed use in palliative care, see palliative care formulary here	
4.2.1	Paliperidone	1	SHSC have stated that they would not be routinely initiating prescriptions.	
9.2.1.1	Patiromer	1, 5		NICE TA623
8.1.5	Pazopanib	1, 5		NICE TA215
8.2.4	Peginterferon alfa	1, 5	NHSE commissioned. NICE CG165	NICE TA96
5.3.3.2	Peginterferon alfa with ribavirin for treating chronic hepatitis C in children and young people. See also in Red section for adults.	1, 5	http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c-cirrhosis-policy-statmnt-0615.pdf	NICE TA300
5.3.3.2	Peginterferon alfa with ribavirin for treating chronic hepatitis C in adults. See also in Red section for children and young people.	1, 5	NHSE commissioned.	NICE TA200
2.8.1	Pentosan polysulfate sodium	1, 5		NICE TA610
3.11	Pirfenidone	1, 5		NICE TA504
	Ponesimod	1, 5	NHSE commissioned.	NICE TA767
5.2.1	Posaconazole	1, 5	NHSE commissioned.	

8.1	Procarbazine	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
4.2.1	Quetiapine modified release	1	SHSC have stated that they would not be routinely initiating prescriptions.	
5.3.1	Raltegravir	1, 5	NHSE commissioned.	
5.3.1	Rilpivirine (including combinations)	1, 5	NHSE commissioned.	
2.5.1	Riociguat	1, 5	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned.	
5.3.1	Ritonavir	1, 5	NHSE commissioned.	
2.8.2	Rivaroxaban: Prophylaxis of venous thromboembolism following hip and knee replacement surgery. Note: full course to be provided by secondary care.	1, 5	See Amber and Green sections for other indications.	NICE TA170
6.6.2	Romosozumab	1, 5		NICE TA791
9.1.3	Roxadustat	1, 5		NICE TA807
5.3.1	Saquinavir	1, 5	NHSE commissioned.	
Prescribing in PAH	Selexipag	1, 5	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned.	
9.5.2.2	Sevelamer (Renagel®)	1, 5	To be prescribed by renal services, specialised commissioning.	
7.4.5	Sildenafil (prescribed as Viagra®) (For Erectile Dysfunction)	1, 2	If SLS criteria not met a GP may provide a private prescription (detailed in HSC 1999/148) . See also entry in green section.	Prescribing of generic sildenafil
2.5.1	Sildenafil (For Pulmonary Arterial Hypertension)	1, 5	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned. See also sildenafil entries for Erectile Dysfunction.	
5.3.3.2	Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C.	1, 5	http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c-cirrhosis-policy-statmnt-0615.pdf	NICE TA331
8.2.4	Siponimod	1, 5		NICE TA656
8.2.2	Sirolimus	1, 5	NHSE commissioned.	
4.1.1	Sodium Oxybate	1, 5		
5.3.3.2	Sofosbuvir for treating chronic hepatitis C	1, 5	http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c-cirrhosis-policy-statmnt-0615.pdf	NICE TA330
5.3.1	Stavudine	1, 5	NHSE commissioned.	
4.10.3	Suboxone®	1, 5	As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-sheffield-treatment-and-recovery-team	
9.5.2	Sucroferric oxyhydroxide	1, 5	NHSE commissioned.	NICE NG203
8.2.2	Tacrolimus (oral)	1	See GREEN section for topical tacrolimus.	
7.4.5	Tadalafil (For Erectile Dysfunction)	1, 2	If SLS criteria not met a GP may provide a private prescription (detailed in HSC 1999/148) . See also entries in green section and black section (once daily preparations).	
2.5.1	Tadalafil (For Pulmonary Arterial Hypertension)	1, 5	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned. See also tadalafil entries for Erectile Dysfunction.	
8.1	Tegafur with gimeracil and oteracil	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
8.1	Temozolomide	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
5.3.1	Tenofovir Alafenamide (including combinations)	1, 5	NHSE commissioned.	
5.3.1	Tenofovir Disoproxil (including combinations)	1, 5	NHSE commissioned.	
8.2.4	Teriflunomide	1, 5	NHSE commissioned.	NICE TA303
8.2.4	Thalidomide	1		
2.8.1	Tinzaparin	1	Unless guidance available.	

8.1	Tioguanine	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
5.3.1	Tipranavir	1, 5	NHSE commissioned.	
5.1.4	Tobramycin	5	Specialised commissioning. To be prescribed by cystic fibrosis services. See also Amber section for non-cystic fibrosis bronchiectasis indication.	
4.9.1	Tolcapone	1, 5	NHSE commissioned.	
6.5.2	Tolvaptan		SIADH Tolvaptan in the Syndrome of Inappropriate Anti-diuretic Hormone.	NICE TA358
Unlicensed not listed in current BNF	Treprostinil	1, 5	Patients treated for Pulmonary Arterial Hypertension.	
8.1	Tretinoin	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
5.3.2	Valganciclovir	1, 5	NHSE commissioned.	
7.4.5	Vardenafil	1, 2	If SLS criteria not met a GP may provide a private prescription (detailed in HSC 1999/148). See also entry in green section.	
4.10.2	Varenicline	5	Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service. http://sheffield.yorkshiresmokefree.nhs.uk/	
5.3.3	Velpatasvir with sofosbuvir (Epclusa®)	1, 5	NHSE commissioned.	NICE TA430
5.3.3	Velpatasvir with sofosbuvir and voxilaprevir (Vosevi®)	1, 5	NHSE commissioned.	NICE TA507
8.1	Vinorelbine	1, 5	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert . Exceptions include oral anti cancer medicines where a shared care protocol exists.	
5.2.1	Voriconazole	1, 5	NHSE commissioned.	
5.3.1	Zidovudine (including combinations)	1, 5	NHSE commissioned.	
7.4.5	Alprostadil	1	SLS criteria applies - prescriptions may be issued for patients eligible for NHS treatment (as per SI 2004 No 629), otherwise RED. Note - Patients with Severe Distress are not covered by SLS criteria (as detailed in HSC 1999/177).	HSC 1999/177
2.3.2	Amiodarone	1, 2, 3	Amiodarone SCG	
4.2.1	Amisulpride	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
8.3.4.1	Anastrozole	1, 2	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer . See also, section on ibandronic acid.	
2.8.2	Apixaban for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism	1	See Red and Green sections for other indications.	NICE TA341
4.2.1	Aripiprazole	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.4	Atomoxetine	1, 2	SCG for ADHD in Children and Adults	
10.1.3	Azathioprine	1, 2, 3	Azathioprine and Mercaptopurine SCP	
2.12	Bempedoic Acid (Nilemdo®)	1	Monotherapy, for the management of primary hypercholesterolaemia or mixed dyslipidaemia, as an option for lipid specialist to consider. See also bempedoic acid in Green section.	
4.2.1	Benperidol	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
2.12	Bezafibrate	1	For hypertriglyceridemia and/or mixed dyslipidaemia; however, use in this cohort of patients would usually be on the initiation or recommendation of a lipid clinic specialist.	
8.3.4.2	Bicalutamide	1, 2	Hormonal Management of Prostatic Cancer SCP	

13.6.3	Brimonidine tartrate (Mirvaso®)	1	For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea MHRA	See MHRA update on systemic cardiovascular effects
4.8.1	Brivaracetam	1	Epilepsy in Children SCG	
4.2.1	Chlorpromazine hydrochloride	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
11.4.2	Ciclosporin eye drops	1		NICE TA369
9.5.1.2	Cinacalcet	1, 2, 3	Cinacalcet for Primary Hyperparathyroidism in Adults . See Red for prescribing by renal services.	
5.1.7	Colistimethate sodium (colistin sulfomethate sodium) (Colomycin®)	1, 2, 3	For non-cystic fibrosis bronchiectasis. Prescribe as Colomycin® brand. See SCG . See Red section for cystic fibrosis.	
8.3.4.2	Cyproterone acetate	1, 2	Hormonal Management of Prostatic Cancer SCP	
2.8.2	Dabigatran etexilate - for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	1	See Red and Green sections for other indications.	NICE TA327
2.8.1	Dalteparin	1, 2, 3	Dalteparin SCG	
6.7.2	Danazol	1, 2, 3	For unlicensed indications and more details, see CAS Supply Disruption Alert (29 May 2020): Note to prescribers: as there can be a delay in obtaining supplies; please allow 2 weeks for community pharmacy to source the unlicensed product.	
10.2.2	Dantrolene sodium	1, 2, 3		
6.1.2.3	Dapagliflozin	1, 2, 3	Dapagliflozin for treating chronic heart failure with reduced ejection fraction (HFrEF) . Refer to primary care guidance. See also dapagliflozin: for treating chronic heart failure with preserved or mildly reduced ejection fraction in line with NICE TA902 , in amber section; for treating type 2 diabetes in line with NICE NG28, in Green section; and for treating chronic kidney disease in line with NICE TA775 , in Green section.	NICE TA679
6.1.2.3	Dapagliflozin	1,2 (IMOC)	Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF). Approved as AMBER-G by SY IMOC Jul 23. See also dapagliflozin: for treating chronic heart failure with reduced ejection fraction in line with NICE TA679 , in amber section; for treating type 2 diabetes in line with NICE NG28, in Green section; and for treating chronic kidney disease in line with NICE TA775, in Green section.	NICE TA902
7.4.6	Dapoxetine	1, 2	To be prescribed only when all the criteria specified in the SPC are met. A maximum supply of 6 tabs per month is advised by the Sheffield APG.	
8.3.4.2	Degarelix	1, 2	Hormonal Management of Prostatic Cancer SCP	
4.10.1	Disulfiram	1, 2	Alcohol Relapse Prevention Guideline	
4.11	Donepezil	1, 2, 3	Dementia SCG	
6.1.2.3	Dulaglutide	1		
2.8.2	Edoxaban for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism	1	Note: treatment of DVT and PE will be initiated in secondary care. See Green section for other indication.	NICE TA354 .
6.1.2.3	Empagliflozin	1,2,3	Empagliflozin for treating chronic heart failure with reduced ejection fraction (HFrEF) . Refer to primary care guidance. See also empagliflozin: for treating chronic heart failure with preserved or mildly reduced ejection fraction in line with NICE TA929	NICE TA773
6.1.2.3	Empagliflozin	1,2 (IMOC)	Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF) . Approved as AMBER-G by SY IMOC Dec 23. See also empagliflozin: for treating chronic heart failure with reduced ejection fraction in line with NICE TA929	NICE TA929
9.4.2	Enteral Feeding Solutions	1	When dietetic advice is provided. See appendix 2 of the BNF for full list.	
2.5.5.2	Entresto® (sacubitril valsartan)	1, 2, 3	ONLY to be transferred to a GP when patient has been up titrated and on a stable, optimal dose.	NICE TA388
2.2.3	Eplerenone	1	For patients intolerant of spironolactone due to gynaecomastia.	

7.3.1	Ethinylestradiol with Etonogestrel vaginal ring (NuvaRing®)	1		
4.8.1	Ethosuximide	1	Epilepsy in Children SCG	NICE CG137
8.3.4.1	Exemestane	1, 2	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer . See also, section on ibandronic acid.	
6.1.2.3	Exenatide	1		
2.12	Fenofibrate	1	For hypertriglyceridemia and/or mixed dyslipidaemia; however, use in this cohort of patients would usually be on the initiation or recommendation of a lipid clinic specialist.	
5.1.7	Fidaxomicin	1	If prescribed in line with NICE NG199 as a second line antibiotic for a first episode of mild, moderate or severe C.difficile infection if vancomycin ineffective or for a further episode (see NICE guidance). Following specialist recommendation, fidaxomicin may be prescribed by a primary care clinician. See also vancomycin (oral) in Green section.	NICE NG199
4.2.1	Flupentixol	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
8.3.4.1	Fulvestrant	1, 2	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer . See also, section on ibandronic acid.	
4.11	Galantamine	1, 2, 3	Dementia SCG	
8.3.4.2	Goserelin	1, 2	Hormonal Management of Prostatic Cancer SCP . NB see also goserelin in endocrine management of breast cancer.	
8.3.4.1	Goserelin	1, 2	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer . See also, section on ibandronic acid. See also goserelin in the management of prostatic cancer.	
4.4	Guanfacine	1, 2, 3	Shared Care for the Management of Prescribing for ADHD	
4.2.1	Haloperidol	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
10.1.3	Hydroxychloroquine	1, 2, 3	Hydroxychloroquine Prescribing in Adults SCG	
6.6.2	Ibandronic acid	1, 2	Prescribing Guideline - Ibandronic acid in post menopausal women with breast cancer – unlicensed indication. Note, use only ibandronic 50mg tablets.	See also Referral and Management of Breast Cancer .
2.12	Icosapent ethyl	1		NICE TA805
Respiratory devices	Inspiratory Muscle Trainer (IMT) Device. e.g. Powerbreathe Medic, Phillips Threshold IMT.	1	See IMT prescribing guidance	
6.1.1.1	Insulin aspart (Fiasp®)	1	For children only, as identified by the secondary care specialist. The first prescription can, with agreement of the primary care clinician, be issued in primary care, subject to receiving a detailed communication, from the specialist, which includes information on the ongoing support and monitoring that secondary care will provide.	
6.1.2	Insulin degludec	1, 2, 3	For use in restricted patient populations. Please take care with the strength of insulin degludec, see: MHRA guidance . Also see amber section for Xultophy®.	
6.1.1	Insulin glargine 300u/ml injection (Toujeo®)		Please prescribe by brand and take care with the strength of insulin.	See MHRA advice
2.6.3	Ivabradine	1	TA267 - Ivabradine for treating chronic heart failure.	NICE CG126 Stable angina management
8.3.4.3	Lanreotide	1, 2, 3	Acromegaly SCP . Specialist to initiate and stabilise dose.	
10.1.3	Leflunomide	1, 2, 3	Leflunomide SCP	

8.3.4.1	Letrozole	1, 2	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer . See also, section on ibandronic acid.	
8.3.4.2	Leuprorelin	1, 2	Hormonal Management of Prostatic Cancer SCP .	
15.2	Lidocaine plasters	1, 2, 3	In exceptional circumstances agreed with pain clinic or palliative care. See prescribing guidance . Also, see Black and Red sections.	NICE CG173
6.1.2	Liraglutide (Victoza®)	1	For Type 2 diabetes in adults:management. See also liraglutide (Victoza®) for children, in Amber section and liraglutide (Saxenda®) in Black and Red sections.	NICE NG28
6.1.2	Liraglutide (Victoza®) for children	1, 2	As third line management in children and young people aged 10 years and over. See also liraglutide / Saxenda in Black and Red sections.	
4.4	Lisdexamfetamine	1, 2, 3	Shared Care / Prescribing Guideline for the management for prescribing in ADHD	NICE TA98
4.2.3	Lithium carbonate	1, 2	Bipolar Disorder SCG	
6.1.2.3	Lixisenatide	1		
4.10.3	Lofexidine hydrochloride	1, 2	For the treatment of opioid dependence,If advice available from specialist services, and prescribed in accordance with national treatment guidelines – otherwise RED. Local guidelines available for GPs who agree to prescribe.	
4.8.2	Lorazepam	1	Epilepsy in Adults SCP	NICE CG137
4.8.2	Lorazepam	1	Epilepsy in Children SCG	NICE CG137
4.1.1	Melatonin (Circadin® 2mg MR tabs and 5mg/5ml oral solution only - in children)	1, 2, 3	Melatonin in treatment of Sleep Disorders in Children SCG . Also see Black and Green sections.	
4.1.1	Melatonin (Slenyto® 1mg and 5mg MR tabs)	1, 2, 3	Amber for licensed indications, see Melatonin in treatment of Sleep Disorders in Children SCG . Also see Black and Green sections.	
4.11	Memantine	1, 2, 3	Dementia SCG	
8.1.3	Mercaptopurine	1, 2, 3	Should not be prescribed in primary care as an oral anticancer medication. Should only be prescribed for inflammatory bowel disease following agreement with a local specialist. Azathioprine and mercaptopurine SCP	
10.1.3	Methotrexate	1, 2, 3	Methotrexate SCG	
2.7.2	Midodrine	1, 2, 3	Midodrine SCP	
4.4	Modafinil	1, 2	Only for licensed use in narcolepsy Modafinil SCP (September 2013). See red section for unlicensed indications approved by Medicines Safety Committee STHFT listed in the SCP, and black section for other unlicensed indications.	
8.2.1	Mycophenolate	1, 2, 3	Mycophenolate Mofetil SCG . See Red section for transplant recipients.	
1.6.6	Naldemedine	1		NICE TA651
1.6.6	Naloxegol	1		NICE TA345
4.10.3	Naltrexone hydrochloride	1, 2	For the treatment of opioid dependence, If advice available from specialist services, and prescribed in accordance with national treatment guidelines – otherwise RED. Local guidelines available for GPs who agree to prescribe. For alcohol relapse prevention see Green section.	
8.3.4.3	Octreotide	1, 2, 3	Acromegaly SCP . Specialist to initiate and stabilise dose.	
4.2.1	Olanzapine (oral medication only)	1, 2	Specialist to initiate and stabilise dose.	
2.12	Omega-3-Fatty Acid capsules (e.g.Omacor®, Prestylon®, Nebbaro® and Maxepa®)	1	For hypertriglyceridaemia to prevent acute pancreatitis.	
Respiratory devices	Oscillating Positive Expiratory Pressure (OPEP) Device e.g. Acapella®, Aerobika	1	See OPEP prescribing guidance	
10.1.3	Penicillamine	1, 2	For the treatment of Wilsons Disease and Cystinuria in adults.	
4.9.1	Pergolide	1	Parkinson's Disease SCP	
4.2.1	Pericyazine	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	

4.2.1	Perphenazine	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	Pimozide	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	Pipotiazine Palmitate	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
2.9	Prasugrel	1		NICE TA317
4.2.1	Prochlorperazine	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	Promazine hydrochloride	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
1.6.7	Prucalopride	1, 2	See prescribing guidance to support specialist initiation and ongoing prescribing in primary care.	
4.2.1	Quetiapine	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
2.6.3	Ranolazine	1	Cardiologist initiation in line with NICE CG126.	NICE CG126
A 2.4.2 Vitamin and mineral supplements	Renavit®	1	Dietary management of water soluble vitamin deficiency in renal patients receiving dialysis.	
5.1.7	Rifaximin (Targaxan®)	1, 2, 3	For preventing episodes of overt hepatic encephalopathy. Rifaximin guideline	NICE TA337
4.2.1	Risperidone	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
2.8.2	Rivaroxaban 2.5mg tablets for preventing adverse outcomes after acute management of acute coronary syndrome	1	See also local guidelines . Note: treatment will be initiated in secondary care. See Red and Green sections for other indications.	NICE TA335
2.8.2	Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism	1	See Red and Green sections for other indications.	NICE TA261
2.8.2	Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism	1	See Red and Green sections for other indications.	NICE TA287
2.8.2	Rivaroxaban 2.5mg tablets for patients with coronary artery disease (CAD) or peripheral artery disease (PAD) at high risk of ischaemic events.	1	See Red and Green sections for other indications.	NICE TA607
4.11	Rivastigmine	1, 2, 3	Dementia SCG	
3.3.3	Roflumilast	1		NICE TA461
6.1.2.3	Semaglutide (Ozempic®) and (Rybelsus®)	1		NICE NG28
6.5.1	Somatropin (Children) Human growth hormone (somatropin) for the treatment of growth failure in children	1, 2	The treatment of Children with Recombinant Human Growth Hormone SCG	NICE TA188
6.5.1	Somatropin (Adults)	1, 2	The treatment of Adults with Growth Hormone (Somatropin)SCG	
6.6.2	Strontium Ranelate	1		
1.3.3	Sucralfate	1	Only on specialist advice for licenced and off-label indications, which include: in highly selected cases with severe refractory oesophageal ulceration with dysphagia and bleeding and as a temporary measure to help with post banding bleeding in varices . Review after 8-12 weeks of continued use.	
10.1.3	Sulfasalazine	1, 2, 3	Sulfasalazine SCG	
4.2.1	Sulpiride	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
6.4.2	Testosterone: topical preparations for post-menopausal women	1, 2, 3	Topical testosterone replacement therapy in postmenopausal women SCP . See also green section	NICE NG23
4.8.1	Tiagabine	1	Epilepsy in Children SCG	NICE CG137
2.9	Ticagrelor	1	NICE TA420 for preventing atherothrombotic events after myocardial infarction.	NICE TA236 for the treatment of acute coronary syndromes
10.2.2	Tizanidine	1, 2, 3	Specialist prescribing for first 4 months.	
3.7	Tobramycin	1, 2, 3	For non-cystic fibrosis bronchiectasis; see SCG . See Red section for cystic fibrosis.	
4.9.1	Tolcapone	1	Parkinson's Disease SCP	

8.3.4.1	Toremifene	1, 2	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer . See also, section on ibandronic acid.	
4.2.1	Trifluoperazine	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
8.3.4.2	Triptorelin Acetate 11.25mg	1, 2	Hormonal Management of Prostatic Cancer SCP.	
8.3.4.2	Triptorelin Pamoate 22.5mg	1, 2	Hormonal Management of Prostatic Cancer SCP.	
4.3.4	Venlafaxine at doses of 300 mg daily or above	1, 2, 3	Higher doses of venlafaxine have greater potential to exacerbate cardiac arrhythmias and hypertension. See also venlafaxine in green section.	
6.1.2.	Xultophy® (insulin degludec 100 unit per 1 ml , liraglutide 3.6mg per 1 ml)	1, 2, 3	Also see amber section: insulin degludec.	
4.2.1	Zuclopenthixol	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	Zuclopenthixol acetate	1, 2	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.10.1	Acamprosate		If initiated in primary care, to be prescribed by a GP/prescriber with special interest OR experience in alcohol relapse prevention and in conjunction with an offer of psychological interventions. See the prescribing guideline for more information.	
2.8.2	Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation		Local guidelines for the prevention of stroke in non-valvular atrial fibrillation. See Red and Amber sections for other indications.	NICE TA275
2.12	Bempedoic Acid NICE TA694		Green, ONLY in combination with ezetimibe and in line with the updated lipid guidelines for BOTH the primary and secondary prevention of CVD. See Lipid optimisation for the SECONDARY prevention of cardiovascular disease in adults . See also bempedoic acid in Amber section for monotherapy.	See also Lipid optimisation for the PRIMARY prevention of cardiovascular disease in adults .
6.1.2.3	Canagliflozin			NICE TA315
2.8.2	Dabigatran etexilate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation		Local guidelines for the prevention of stroke in non-valvular atrial fibrillation . See Red and Amber sections for other indications.	NICE TA249
6.1.2.3	Dapagliflozin		Dapagliflozin for treating type 2 diabetes. See also dapagliflozin: for treating chronic kidney disease in line with NICE TA775 in Green section; for treating heart failure with reduced ejection fraction, in line with NICE TA679, in Amber section; and for treating heart failure with preserved or mildly reduced ejection fraction, in line with NICE TA902 in Amber section.	NICE NG28
6.1.2.3	Dapagliflozin		Dapagliflozin for treating chronic kidney disease. Refer to CKD primary care guideline to support prescribing. See also dapagliflozin: for treating type 2 diabetes in line with NICE NG28, in Green section; for treating heart failure with reduced ejection fraction, in line with NICE TA679, in Amber section; and for treating heart failure with preserved or mildly reduced ejection fraction, in line with NICE TA902 in Amber section.	NICE TA775
2.8.2	Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation		Local guidelines for the prevention of stroke in non-valvular atrial fibrillation . See Amber section for other indication.	NICE TA355
6.1.2.3	Empagliflozin		Empagliflozin for treating type 2 diabetes. See also empagliflozin: for treating chronic kidney disease in line with NICE TA942 in Green section; for treating heart failure with reduced ejection fraction, in line with NICE TA773, in Amber section; and for treating heart failure with preserved or mildly reduced ejection fraction, in line with NICE TA929 in Amber section.	NICE NG28

6.1.2.3	Empagliflozin		Empagliflozin for treating chronic kidney disease. Approved as GREEN by SY IMOC Feb 24. See also empagliflozin: for treating type 2 diabetes in line with NICE NG28, in Green section; for treating heart failure with reduced ejection fraction, in line with NICE TA773, in Amber section; and for treating heart failure with preserved or mildly reduced ejection fraction, in line with NICE TA929 in Amber section.	NICE TA942
10.1.4	Febuxostat		Now first line with allopurinol.	NICE NG219
13.8.1	Fluorouracil (5-Fluorouracil) cream 5% (Efudix®)		See: Actinic keratosis pathway	
2.12	Inclisiran		For secondary prevention of cardiovascular disease in line with NICE TA733 - further guidance on implementation to follow.	NICE TA733
1.6.7	Linaclotide		As a third line treatment for moderate to severe irritable bowel syndrome with constipation in adults. See local guidelines .	
4.1.1	Melatonin (Circadin 2mg MR tabs - in adults)		For licensed indication. Also see Black and Amber sections.	
7.4.2	Mirabegron		For use in those aged 18 years and over, in line with NICE TA 290 for treating the symptoms of overactive bladder only where antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects.	NICE TA290
4.7.2	Morphine orodispersible tablets (Actimorph®)		Morphine orodispersible tablets (Actimorph®) are an option for use in vulnerable patient groups, to reduce the risk of accidental or intentional overdose; or where there are dexterity issues.	
4.10.3	Naltrexone hydrochloride		If initiated in primary care, to be prescribed by a GP/prescriber with special interest OR experience in alcohol relapse prevention and in conjunction with an offer of psychological interventions. See the prescribing guideline for more information.	
10.3.2	NSAIDs (topical) diclofenac sodium, felbinac, ibuprofen, ketoprofen and piroxicam		In line with NICE guidance for osteoarthritis. Topical ibuprofen is the Sheffield formulary choice. See also entry in Black section.	NICE NG226
13.5.3	Pimecrolimus (topical)		When a prescriber is GPwSI in dermatology, or on their recommendation, or is competent in prescribing in dermatological conditions	NICE TA82
2.8.2	Rivaroxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation		Local guidelines for the prevention of stroke in non-valvular atrial fibrillation . See Red and Amber sections for other indications.	NICE TA256
7.4.5	Sildenafil (Prescribed as Viagra®) (For Erectile Dysfunction)		SLS criteria applies - prescriptions may be issued for patients eligible for NHS treatment (as per SI 2004 No 629), otherwise RED. Note - Patients with Severe Distress are not covered by SLS criteria (as detailed in HSC 1999/177).	HSC 1999/177
7.4.5	Sildenafil (Prescribed generically) (For Erectile Dysfunction)		SLS criteria does not apply for sildenafil prescribed generically (detailed in SI 2014 No. 1625). See also sildenafil prescribed as Viagra® in green and red sections.	Prescribing of generic sildenafil
13.5.3	Tacrolimus (topical)		When a prescriber is GPwSI in dermatology, or on their recommendation, or is competent in prescribing in dermatological conditions. See also Red section for oral tacrolimus.	NICE TA82
7.4.5	Tadalafil (For Erectile Dysfunction)		SLS criteria applies - NHS FP10 prescriptions may be issued for patients who meet SLS criteria (as per SI 2004 No 629), otherwise RED. Note - Patients with Severe Distress are not covered by SLS criteria (as detailed in HSC 1999/177). See also once daily preparations in black section.	HSC 1999/177
6.4.2	Testosterone: topical preparations for post-menopausal women		Only where primary care prescriber has knowledge and competency to initiate testosterone without referral to the menopause clinic. See also amber section and Topical testosterone replacement therapy in postmenopausal women SCP .	NICE NG23
5.1.7	Vancomycin (oral)		If prescribed in line with NICE NG199 as a first line antibiotic for a first episode of mild, moderate or severe C.difficile infection. See also fidaxomicin in Amber section.	NICE NG199
7.4.5	Vardenafil		SLS criteria applies - prescriptions may be issued for patients eligible for NHS treatment (as per SI 2004 No 629), otherwise RED. Note - Patients with Severe Distress are not covered by SLS criteria (as detailed in HSC 1999/177).	HSC 1999/177

5.2.1	Venlafaxine modified and immediate release		SHSC have stated that they would not be routinely initiating prescriptions for modified release preparations. For total daily doses of 300mg or above see Amber section.	
4.3.4	Vortioxetine		NICE NG222 Depression in adults: treatment and management	NICE TA367 Vortioxetine for treating major depressive episodes